
VALIRX PLC — Investor Relations & Filings
ValiRx PLC is a life science company that accelerates the development of therapeutics and diagnostics, with a primary focus on oncology and women's health. The company's business model centers on identifying and progressing promising early-stage scientific discoveries through pre-clinical and clinical development. ValiRx provides scientific, financial, and commercial expertise to translate novel research into clinically validated treatments, aiming to improve patient outcomes in its target therapeutic areas.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Change of Registered Office | 2026-03-31 | English | |
| ValiRx Commercial Update Q1 2026 | 2026-03-26 | English | |
| ValiRx and TwinEdge to present Digital Twin data | 2026-03-24 | English | |
| Director/PDMR Shareholding | 2026-03-04 | English | |
| ValiRx forms ValiRx Animal Health Ltd subsidiary | 2026-03-02 | English | |
| Exercise of Warrants | 2026-01-19 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
9 filings
| |||||
| 33109023 | Change of Registered Office | 2026-03-31 | English | ||
| 33045657 | ValiRx Commercial Update Q1 2026 | 2026-03-26 | English | ||
| 33018480 | ValiRx and TwinEdge to present Digital Twin data | 2026-03-24 | English | ||
| 32875259 | Director/PDMR Shareholding | 2026-03-04 | English | ||
| 32859834 | ValiRx forms ValiRx Animal Health Ltd subsidiary | 2026-03-02 | English | ||
| 13006423 | Exercise of Warrants | 2026-01-19 | English | ||
| 34556027 | Replacement: Evaluation and Transfer Agreement | 2026-01-09 | English | ||
| 34555998 | New Evaluation and Material Transfer Agreement | 2026-01-09 | English | ||
| 34555958 | Holding(s) in Company | 2026-01-08 | English | ||
|
2025
6 filings
| |||||
| 9347356 | Holding(s) in Company | 2025-12-05 | English | ||
| 8576672 | Holding(s) in Company | 2025-11-24 | English | ||
| 8558646 | Holding(s) in Company | 2025-11-24 | English | ||
| 8482575 | Result of GM & Issue of Equity | 2025-11-20 | English | ||
| 8295975 | Holding(s) in Company | 2025-11-13 | English | ||
| 8166114 | Holding(s) in Company | 2025-11-10 | English | ||
Financials
We couldn't load the financials
No data available yet
We have extracted financials for VALIRX PLC, but not for this combination of statement and period. Try a different combination.
Swipe the table to view all periods, or rotate your phone for a wider view.
| Line item | ! |
|---|---|
| Definition not yet available — coming soon. |
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Genprex, Inc.
Clinical-stage gene therapy company developing therapies fo…
|
GNPX | US | Professional, scientific and te… |
|
Genxone Spolka Akcyjna
A biotechnology company specializing in Next Generation Seq…
|
GX1 | PL | Professional, scientific and te… |
|
GeoVax Labs, Inc.
Clinical-stage biotech developing vaccines and therapies fo…
|
GOVX | US | Professional, scientific and te… |
|
GH Research PLC
Develops mebufotenin-based therapies for psychiatric and ne…
|
GHRS | IE | Professional, scientific and te… |
|
GI Innovation Inc.
Researches and develops protein-based drugs for immuno-onco…
|
358570 | KR | Professional, scientific and te… |
|
Ginkgo Bioworks Holdings, Inc.
Operates a horizontal platform for cell programming and syn…
|
DNA | US | Professional, scientific and te… |
|
GRAIL, Inc.
A healthcare company developing blood tests for multi-cance…
|
GRAL | US | Professional, scientific and te… |
|
GT Biopharma, Inc.
Clinical-stage immuno-oncology company developing therapies…
|
GTBP | US | Professional, scientific and te… |
|
Guard Therapeutics International AB
Clinical-stage biotech developing therapies to prevent acut…
|
GUARD | SE | Professional, scientific and te… |
|
Gubra A/S
Biotech and CRO focused on peptide drugs for metabolic and …
|
GUBRA | DK | Professional, scientific and te… |
VALIRX PLC via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/7998/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=7998 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=7998 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=7998 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 7998}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for VALIRX PLC (id: 7998)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.